NCT02803437View on ClinicalTrials.gov

Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

CompletedOBSERVATIONAL
Enrollment

334

Participants

Timeline

Start Date

July 21, 2016

Primary Completion Date

January 6, 2022

Study Completion Date

December 18, 2024

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
DRUG

Radium-223 dichloride (Xofigo, BAY 88-8223)

Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02803437 - Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases | Biotech Hunter | Biotech Hunter